Our group studies the development and the normal and pathological aging of the nervous system at different scales (molecular, cellular, and neural network levels). With regard to development, we are particularly interested in the cerebral cortex and its connectivity.
We apply molecular, biochemical, and morphological methods to investigate neurodegenerative diseases (such as motor neuron diseases like SMA and ALS, as well as Alzheimer’s and Parkinson’s), stroke, spinal cord injuries and neuropathic pain.
In this context, we study:
- the role of excitotoxicity and autophagy
- mitochondrial dysfunctions
- iron accumulation
- neuroinflammation
- the glymphatic system in neurodegeneration.
Some of these conditions are associated with frailty and muscle disorders, which we consider both as part of the pathology and as potential therapeutic targets.
Our aim is not only to understand disease mechanisms but also to identify biomarkers and molecular pathways for the development of new therapeutic strategies.
Experimental models
In addition to using both genetic and non-genetic animal models of disease, we also employ in vitro models (iPSCs and organoids). To discover new treatments, we are studying cell therapies (such as stem cell transplantation) and drug repurposing strategies using compounds already approved for other conditions (to accelerate the drug discovery process).
Moreover, in collaboration with clinical groups, we also investigate non-pharmacological therapies through the use of medical devices, assistive robotics, and “green therapy.”
Our projects generate an impressive amount of data, which we share and analyze in collaboration with other groups at both national and international level.
